|
Molecular properties generated using the CDK |
Classification ![]() |
|
| Compound class | Synthetic organic |
| Approved drug? | Yes (source: FDA (1994)) |
IUPAC Name ![]() |
| S-(fluoromethyl) (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-17-carbothioate |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 5636 | fluticasone |
Synonyms ![]() |
| Advair® |
| Flovent HFA® |
| Veramyst® |
Database Links ![]() |
|
| CAS Registry No. | 90566-53-3 (source: SciFinder) |
| ChEMBL Ligand | CHEMBL1201396 |
| DrugBank Ligand | DB00588 |
| PubChem CID | 5311101 |
| Search Google for chemical match using the InChIKey | MGNNYOODZCAHBA-GQKYHHCASA-N |
| Search Google for chemicals with the same backbone | MGNNYOODZCAHBA |
| Search PubMed clinical trials | fluticasone |
| Search PubMed titles | fluticasone |
| Search PubMed titles/abstracts | fluticasone |
| Wikipedia | Fluticasone |
| Comments |
| The DrugBank entry listed here refers to fluticasone propionate with CAS registry number 80474-14-2. ChEMBL lists fluticasone propionate as a glucocorticoid receptor agonist, but not the fluticasone parent molecule. Breo Ellipta®, approved by the FDA in 2013, is a fixed-dose formulation containing fluticasone furoate and vilanterol. |